

Special Issue

Translational Therapies for Mesothelioma

Message from the Guest Editor

Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis because of the poor response to all the treatments tested so far. Most of the clinical trials run for this tumour have been based on drugs with some efficacy for other malignancies but without a specific background for MPM. We reckon that this “random approach” is one of the most relevant reasons why the prognosis of these patients has been substantially unchanged from 2003 when the current front-line chemotherapy was approved. Every step forward in therapy for human cancer has always been laid on the preclinical working ground, and thus we are firmly convinced the same workstream will generate more solid achievements for this neoplasm as well. In the light of the most recent findings, tumour metabolism, immunometabolism and microenvironment will be particularly screened as new druggable targets. Therefore, we are asking some world-class groups known for working on innovative topics with the potential of being game-changers for MPM to provide us with their results and their understanding of the best direction to take in order to achieve better treatments for these patients.

Guest Editor

Prof. Dr. Luciano Mutti

Department of Biology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA

Deadline for manuscript submissions

closed (5 December 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/83085

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)